Navigation Links
Neurobiological Technologies Receives Nasdaq Closing Bid Price Notification
Date:9/17/2009

EMERYVILLE, Calif., Sept. 17 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (Nasdaq: NTII) ("NTI") announced today that, on September 15, 2009, it received a letter from The Nasdaq Stock Market indicating that the bid price of NTI's common stock has closed below $1.00 per share for 30 consecutive business days. The letter indicated that a closing bid price below $1.00 per share is a deficiency under Nasdaq's requirements for continued listing pursuant to Marketplace Rule 5550(a)(2). The letter from Nasdaq further stated that, under Marketplace Rule 5810(c)(3)(A), NTI will be provided 180 calendar days, or until March 15, 2010, to regain compliance with Marketplace Rule 5550(a)(2). To regain compliance, the bid price of NTI's common stock must close at $1.00 per share or more for a minimum of 10 consecutive business days.

The letter also stated that on March 15, 2010, if NTI meets the Nasdaq Capital Market initial inclusion criteria set forth in Marketplace Rule 5505, except for the bid price requirement, it may be provided with an additional 180 calendar day period to demonstrate compliance. On March 15, 2010, if NTI is not eligible for an additional compliance period, Nasdaq Staff will provide written notification that NTI's securities will be delisted. Upon such notice, NTI may appeal the Nasdaq Staff's Determination to a Listing Qualifications Panel, pursuant to the procedures set forth in the Nasdaq Marketplace Rule 5800 Series.

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc. is a biopharmaceutical company historically focused on developing investigational drugs for central nervous system conditions. On September 8, 2009, the Company filed a preliminary proxy statement relating to its intention to call a special meeting of stockholders to seek approval of a voluntary dissolution and liquidation of the Company.


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Neurobiological Technologies Announces Termination of its License and Cooperation Agreement with Merz and Childrens Medical Center
2. Neurobiological Technologies Announces Hiring of Advisor to Seek Sale of Company
3. Neurobiological Technologies Reports Second Quarter Fiscal 2009 Financial Results
4. Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
5. Neurobiological Technologies Announces Suspension of Viprinex Development
6. Neurobiological Technologies Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009
7. Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results
8. Neurobiological Technologies to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York on November 10
9. Neurobiological Technologies Sets Date for First Quarter Financial Results
10. Neurobiological Technologies Reports Receipt of $2 Million Royalty Payment for Quarterly Sales of Memantine
11. Neurobiological Technologies to Present at the BIO Investor Forum in San Francisco on October 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... BioMarketing, a leading provider of patient support solutions, has announced ... network, which will launch this week. The VMS CNEs will ... to enhance the patient care experience by delivering peer-to-peer education ... professionals to help women who have been diagnosed and are ... ...
(Date:10/11/2017)... ... 2017 , ... A new study published in Fertility and ... in vitro fertilization (IVF) transfer cycles. The multi-center matched cohort study ... comparing the results from the fresh and frozen transfer cohorts, the authors of ...
(Date:10/10/2017)... Angeles, CA (PRWEB) , ... ... ... Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, ... uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in ...
(Date:10/10/2017)... Parks Associates announced today that Tom Kerber , Director ... , October 11 in Scottsdale, Arizona . Kerber will ... safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and the introduction of ...
Breaking Biology Technology:
(Date:4/24/2017)... 24, 2017 Janice Kephart , ... Identity Strategy Partners, LLP (IdSP) , today issues ... President Trump,s March 6, 2017 Executive Order: ... vetting can be instilled with greater confidence, enabling ... all refugee applications are suspended by until at ...
(Date:4/13/2017)... According to a new market research report "Consumer ... Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - ... to grow from USD 14.30 Billion in 2017 to USD 31.75 Billion ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... 2017 Forecasts by Product Type ... by End-Use (Transportation & Logistics, Government & Public Sector, ... Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation ... Are you looking for a definitive report on the ... ...
Breaking Biology News(10 mins):